PROPANC BIOPHARMA, INC.
Cash Flow Statement
| Line Item | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-526.7K | $-584.4K | $-350.9K | $-748.0K | $-809.8K | $-485.4K | $-617.3K | $-904.8K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $49 | $114 | $134 | $320 | $450 | $422 | $473 | $490 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | $0 | $0 | $0 | $2.4K | $10.4K |
| Net Cash from Operating Activities | $-102.8K | $-238.9K | $-333.5K | $-178.0K | $-192.7K | $-225.2K | $-509.3K | $-411.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $66.6K | $273.9K | $350.3K | $100.0K | $269.5K | $250.0K | $494.2K | $374.3K |
| Net Change in Cash | $-65.4K | $65.0K | $-3.4K | $-83.2K | $68.8K | $5.1K | $15.3K | $-129.8K |
| Free Cash Flow | — | — | — | — | — | — | — | — |